Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) major shareholder Ra Capital Management, L.P. acquired 61,523 shares of Hemab Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the transaction, the insider owned 6,444,637 shares in the company, valued at $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Monday, June 15th, Ra Capital Management, L.P. purchased 6,146 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.89 per share, with a total value of $152,973.94.
- On Wednesday, May 20th, Ra Capital Management, L.P. purchased 996 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.94 per share, with a total value of $24,840.24.
- On Tuesday, May 19th, Ra Capital Management, L.P. purchased 3,802 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.97 per share, with a total value of $94,935.94.
- On Tuesday, May 12th, Ra Capital Management, L.P. purchased 6,387 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.90 per share, with a total value of $159,036.30.
- On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.81 per share, with a total value of $989,149.89.
- On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.98 per share, with a total value of $37,045.34.
- On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.46 per share, with a total value of $242,300.76.
- On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.60 per share, with a total value of $1,673,242.80.
- On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.63 per share, with a total value of $2,399,232.93.
- On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $18.00 per share, with a total value of $48,150,000.00.
Hemab Therapeutics Price Performance
Shares of Hemab Therapeutics stock traded up $0.94 on Wednesday, reaching $26.45. The company’s stock had a trading volume of 372,565 shares, compared to its average volume of 221,371. Hemab Therapeutics Holdings, Inc. has a 52 week low of $23.00 and a 52 week high of $36.61.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the stock. Jefferies Financial Group assumed coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 target price for the company. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. The Goldman Sachs Group initiated coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective for the company. Wedbush initiated coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price objective for the company. Finally, Zacks Research raised Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $41.40.
Read Our Latest Analysis on Hemab Therapeutics
About Hemab Therapeutics
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Further Reading
- Five stocks we like better than Hemab Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
